A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 25, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Maxim Group Syndicate Department: 405 Lexington Ave., New York, NY, 10174; by telephone 212-895-3575, Fax 212-895-3828 or email request at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Companyâ€™s research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. ImaRx Therapeuticsâ€™ commercialization efforts are currently focused on its product, AbbokinaseÂ®, for the treatment of acute massive pulmonary embolism.